Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry

Contrasting INVO Bioscience (NASDAQ:INVO) and Glaukos (NYSE:GKOS)

Defense World ·  {{timeTz}}

INVO Bioscience (NASDAQ:INVO – Get Rating) and Glaukos (NYSE:GKOS – Get Rating) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, analyst recommendations and earnings.

Earnings & Valuation

This table compares INVO Bioscience and Glaukos' revenue, earnings per share and valuation.

Get INVO Bioscience alerts:
Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
INVO Bioscience $4.16 million 4.51 -$6.66 million N/A N/A
Glaukos $294.01 million 9.18 -$49.59 million ($1.19) -47.93

INVO Bioscience has higher earnings, but lower revenue than Glaukos.

Profitability

This table compares INVO Bioscience and Glaukos' net margins, return on equity and return on assets .
Net Margins Return on Equity Return on Assets
INVO Bioscience -222.62% -165.97% -92.06%
Glaukos -19.35% -13.82% -7.73%

Insider & Institutional Ownership

11.8% of INVO Bioscience shares are owned by institutional investors. Comparatively, 93.1% of Glaukos shares are owned by institutional investors. 10.4% of INVO Bioscience shares are owned by company insiders. Comparatively, 8.1% of Glaukos shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Volatility and Risk

INVO Bioscience has a beta of 0.19, indicating that its stock price is 81% less volatile than the S&P 500. Comparatively, Glaukos has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and price targets for INVO Bioscience and Glaukos, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
INVO Bioscience 0 1 2 0 2.67
Glaukos 1 4 4 0 2.33

INVO Bioscience presently has a consensus target price of $2.50, suggesting a potential upside of 62.34%. Glaukos has a consensus target price of $57.38, suggesting a potential upside of 0.59%. Given INVO Bioscience's stronger consensus rating and higher possible upside, equities analysts clearly believe INVO Bioscience is more favorable than Glaukos.

Summary

Glaukos beats INVO Bioscience on 8 of the 12 factors compared between the two stocks.

About INVO Bioscience

(Get Rating)

INVO Bioscience, Inc., a commercial-stage fertility company, provides assisted reproductive technology solutions worldwide. Its flagship product is the INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. The company was founded in 2007 and is based in Sarasota, Florida.

About Glaukos

(Get Rating)

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.

Receive News & Ratings for INVO Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INVO Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.

This presentation is for informational and educational use only and is not a recommendation or endorsement of any particular investment or investment strategy. Investment information provided in this content is general in nature, strictly for illustrative purposes, and may not be appropriate for all investors. It is provided without respect to individual investors’ financial sophistication, financial situation, investment objectives, investing time horizon, or risk tolerance. You should consider the appropriateness of this information having regard to your relevant personal circumstances before making any investment decisions. Past investment performance does not indicate or guarantee future success. Returns will vary, and all investments carry risks, including loss of principal. Moomoo makes no representation or warranty as to its adequacy, completeness, accuracy or timeliness for any particular purpose of the above content.

Moomoo is a financial information and trading app offered by Moomoo Technologies Inc.
In the U.S., investment products and services available through the moomoo app are offered by Moomoo Financial Inc., a broker-dealer registered with the U.S. Securities and Exchange Commission (SEC) and a member of Financial Industry Regulatory Authority (FINRA)/Securities Investor Protection Corporation (SIPC).
In Singapore, investment products and services available through the moomoo app are offered through Moomoo Financial Singapore Pte. Ltd. regulated by the Monetary Authority of Singapore (MAS). Moomoo Financial Singapore Pte. Ltd. is a Capital Markets Services Licence (License No. CMS101000) holder with the Exempt Financial Adviser Status. This advertisement has not been reviewed by the Monetary Authority of Singapore.
In Australia, financial products and services available through the moomoo app are provided by Futu Securities (Australia) Ltd, an Australian Financial Services Licensee (AFSL No. 224663) regulated by the Australian Securities and Investment Commission (ASIC). Please read and understand our Financial Services Guide, Terms and Conditions, Privacy Policy and other disclosure documents which are available on our websites https://www.futuau.com and https://www.moomoo.com/au. Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd. and Futu Securities (Australia) Ltd are affiliated companies.